vs
欧文斯科宁（OC）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
欧文斯科宁的季度营收约是百利高的1.9倍（$2.1B vs $1.1B），欧文斯科宁净利率更高（-13.9% vs -127.8%，领先113.9%），百利高同比增速更快（-2.5% vs -24.6%），欧文斯科宁自由现金流更多（$333.0M vs $148.6M），过去两年百利高的营收复合增速更高（1.3% vs -3.5%）
欧文斯科宁是美国知名建材及复合材料企业，1935年由康宁玻璃厂与欧文斯-伊利诺伊公司合资组建。主营保温材料、屋面材料、玻璃纤维复合材料及相关产品，是全球最大的玻璃纤维复合材料生产商，全球员工约1.9万人，自1955年《财富》500强榜单创立以来连年上榜。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
OC vs PRGO — 直观对比
营收规模更大
OC
是对方的1.9倍
$1.1B
营收增速更快
PRGO
高出22.1%
-24.6%
净利率更高
OC
高出113.9%
-127.8%
自由现金流更多
OC
多$184.4M
$148.6M
两年增速更快
PRGO
近两年复合增速
-3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.1B | $1.1B |
| 净利润 | $-298.0M | $-1.4B |
| 毛利率 | 23.2% | 32.6% |
| 营业利润率 | -10.5% | -116.0% |
| 净利率 | -13.9% | -127.8% |
| 营收同比 | -24.6% | -2.5% |
| 净利润同比 | -15.5% | -3093.9% |
| 每股收益（稀释后） | $-3.47 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OCPRGO
| Q4 25 | $2.1B | $1.1B | ||
| Q3 25 | $2.7B | $1.0B | ||
| Q2 25 | $2.7B | $1.1B | ||
| Q1 25 | $2.5B | $1.0B | ||
| Q4 24 | $2.8B | $1.1B | ||
| Q3 24 | $3.0B | $1.1B | ||
| Q2 24 | $2.8B | $1.1B | ||
| Q1 24 | $2.3B | $1.1B |
净利润OCPRGO
| Q4 25 | $-298.0M | $-1.4B | ||
| Q3 25 | $-494.0M | $7.5M | ||
| Q2 25 | $363.0M | $-8.4M | ||
| Q1 25 | $-93.0M | $-6.4M | ||
| Q4 24 | $-258.0M | $-44.4M | ||
| Q3 24 | $321.0M | $-21.0M | ||
| Q2 24 | $285.0M | $-108.4M | ||
| Q1 24 | $299.0M | $2.0M |
毛利率OCPRGO
| Q4 25 | 23.2% | 32.6% | ||
| Q3 25 | 28.2% | 36.1% | ||
| Q2 25 | 31.2% | 34.4% | ||
| Q1 25 | 28.7% | 37.6% | ||
| Q4 24 | 28.1% | 33.9% | ||
| Q3 24 | 29.8% | 37.2% | ||
| Q2 24 | 31.1% | 37.0% | ||
| Q1 24 | 29.6% | 33.1% |
营业利润率OCPRGO
| Q4 25 | -10.5% | -116.0% | ||
| Q3 25 | -12.2% | 7.0% | ||
| Q2 25 | 18.4% | 4.3% | ||
| Q1 25 | 16.1% | 4.5% | ||
| Q4 24 | -8.5% | 10.0% | ||
| Q3 24 | 16.7% | 7.4% | ||
| Q2 24 | 16.4% | -2.5% | ||
| Q1 24 | 17.5% | -5.1% |
净利率OCPRGO
| Q4 25 | -13.9% | -127.8% | ||
| Q3 25 | -18.4% | 0.7% | ||
| Q2 25 | 13.2% | -0.8% | ||
| Q1 25 | -3.7% | -0.6% | ||
| Q4 24 | -9.1% | -3.9% | ||
| Q3 24 | 10.5% | -1.9% | ||
| Q2 24 | 10.2% | -10.2% | ||
| Q1 24 | 13.0% | 0.2% |
每股收益（稀释后）OCPRGO
| Q4 25 | $-3.47 | $-10.23 | ||
| Q3 25 | $-5.92 | $0.05 | ||
| Q2 25 | $4.25 | $-0.06 | ||
| Q1 25 | $-1.08 | $-0.05 | ||
| Q4 24 | $-2.92 | $-0.32 | ||
| Q3 24 | $3.65 | $-0.15 | ||
| Q2 24 | $3.24 | $-0.79 | ||
| Q1 24 | $3.40 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $345.0M | — |
| 总债务越低越好 | $4.7B | — |
| 股东权益账面价值 | $3.9B | $2.9B |
| 总资产 | $13.0B | $8.5B |
| 负债/权益比越低杠杆越低 | 1.22× | — |
8季度趋势，按日历期对齐
现金及短期投资OCPRGO
| Q4 25 | $345.0M | — | ||
| Q3 25 | $286.0M | $432.1M | ||
| Q2 25 | $230.0M | $454.2M | ||
| Q1 25 | $400.0M | $409.9M | ||
| Q4 24 | $361.0M | $558.8M | ||
| Q3 24 | $499.0M | $1.5B | ||
| Q2 24 | $254.0M | $542.8M | ||
| Q1 24 | $1.3B | $658.5M |
总债务OCPRGO
| Q4 25 | $4.7B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $5.1B | — | ||
| Q1 25 | $5.0B | — | ||
| Q4 24 | $5.1B | — | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $5.0B | — | ||
| Q1 24 | $2.6B | — |
股东权益OCPRGO
| Q4 25 | $3.9B | $2.9B | ||
| Q3 25 | $4.4B | $4.4B | ||
| Q2 25 | $5.2B | $4.5B | ||
| Q1 25 | $4.9B | $4.4B | ||
| Q4 24 | $5.1B | $4.3B | ||
| Q3 24 | $5.6B | $4.6B | ||
| Q2 24 | $5.5B | $4.5B | ||
| Q1 24 | $5.2B | $4.7B |
总资产OCPRGO
| Q4 25 | $13.0B | $8.5B | ||
| Q3 25 | $13.5B | $10.1B | ||
| Q2 25 | $14.5B | $10.1B | ||
| Q1 25 | $14.3B | $9.8B | ||
| Q4 24 | $14.1B | $9.6B | ||
| Q3 24 | $15.1B | $11.2B | ||
| Q2 24 | $15.0B | $10.4B | ||
| Q1 24 | $11.3B | $10.6B |
负债/权益比OCPRGO
| Q4 25 | 1.22× | — | ||
| Q3 25 | 1.06× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 1.01× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.92× | — | ||
| Q1 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $590.0M | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $333.0M | $148.6M |
| 自由现金流率自由现金流/营收 | 15.5% | 13.4% |
| 资本支出强度资本支出/营收 | 12.0% | 2.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $962.0M | $145.1M |
8季度趋势，按日历期对齐
经营现金流OCPRGO
| Q4 25 | $590.0M | $175.4M | ||
| Q3 25 | $918.0M | $51.7M | ||
| Q2 25 | $327.0M | $75.9M | ||
| Q1 25 | $-49.0M | $-64.5M | ||
| Q4 24 | $676.0M | $312.6M | ||
| Q3 24 | $699.0M | $42.2M | ||
| Q2 24 | $493.0M | $9.5M | ||
| Q1 24 | $24.0M | $-1.4M |
自由现金流OCPRGO
| Q4 25 | $333.0M | $148.6M | ||
| Q3 25 | $752.0M | $29.8M | ||
| Q2 25 | $129.0M | $56.7M | ||
| Q1 25 | $-252.0M | $-90.0M | ||
| Q4 24 | $479.0M | $274.9M | ||
| Q3 24 | $558.0M | $15.1M | ||
| Q2 24 | $336.0M | $-18.9M | ||
| Q1 24 | $-128.0M | $-26.5M |
自由现金流率OCPRGO
| Q4 25 | 15.5% | 13.4% | ||
| Q3 25 | 28.0% | 2.9% | ||
| Q2 25 | 4.7% | 5.4% | ||
| Q1 25 | -10.0% | -8.6% | ||
| Q4 24 | 16.9% | 24.2% | ||
| Q3 24 | 18.3% | 1.4% | ||
| Q2 24 | 12.0% | -1.8% | ||
| Q1 24 | -5.6% | -2.4% |
资本支出强度OCPRGO
| Q4 25 | 12.0% | 2.4% | ||
| Q3 25 | 6.2% | 2.1% | ||
| Q2 25 | 7.2% | 1.8% | ||
| Q1 25 | 8.0% | 2.4% | ||
| Q4 24 | 6.9% | 3.3% | ||
| Q3 24 | 4.6% | 2.5% | ||
| Q2 24 | 5.6% | 2.7% | ||
| Q1 24 | 6.6% | 2.3% |
现金转化率OCPRGO
| Q4 25 | — | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 1.73× | — | ||
| Q1 24 | 0.08× | -0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OC
| Insulation | $724.0M | 34% |
| Residential | $625.0M | 29% |
| Doors | $427.0M | 20% |
| Discontinued Operations Disposed Of By Sale | $299.0M | 14% |
| Commercial And Industrial Sector | $101.0M | 5% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
